Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering

Published on June 1, 2026
ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/Lytenava (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, announced a $5.0 million registered direct offering, selling 8.5 million common shares to its largest stockholder, GMS Ventures and Investments. The closing of the offering is expected to occur on or about May 29, 2026, subject to the satisfaction of customary closing conditions, the company said in the announcement.
Continue reading on website
Other news

Obesity May be Tied to Higher Pediatric Astigmatism Incidence

May 29, 2026
With-the-rule astigmatism possesses different characteristics, such as a steep vertical meridian and greater commonality in children, than against-the-rule astigmatism, which is steeper in the horizontal meridian and more common in adults over 40. Photo: Marc Bloomenstein OD. Click image to enlarge. Obesity more than doubled the risk of astigmatism in school-aged children an

L’Amy America Appoints David Low as New Director of Business Development, West

June 1, 2026
NEW YORK—L’Amy America has announced the appointment of David Low as director of business development, West, effective today, June 1, 2026. Low joins L’Amy America at a pivotal moment as it expands its portfolio with the launch of its luxury category and the addition of Billabong eyewear collections, the company said in an announcement. Low brings more than three decades of experience in eyewear s